Arizona State Retirement System Has $532,000 Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Arizona State Retirement System boosted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 22.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,586 shares of the company’s stock after buying an additional 2,348 shares during the period. Arizona State Retirement System’s holdings in Vera Therapeutics were worth $532,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in VERA. First Turn Management LLC lifted its holdings in shares of Vera Therapeutics by 53.3% in the third quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock valued at $14,431,000 after purchasing an additional 113,550 shares in the last quarter. SG Americas Securities LLC lifted its stake in Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock valued at $857,000 after acquiring an additional 10,916 shares in the last quarter. Lord Abbett & CO. LLC lifted its stake in Vera Therapeutics by 41.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after acquiring an additional 124,197 shares in the last quarter. Barclays PLC boosted its holdings in Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after acquiring an additional 41,394 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Vera Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company’s stock worth $15,992,000 after acquiring an additional 10,717 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the completion of the transaction, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 21.70% of the stock is currently owned by corporate insiders.

Vera Therapeutics Stock Performance

Shares of VERA opened at $27.99 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The firm has a market cap of $1.77 billion, a PE ratio of -10.72 and a beta of 1.17. Vera Therapeutics, Inc. has a 1 year low of $25.99 and a 1 year high of $51.61. The stock’s fifty day moving average price is $33.01 and its two-hundred day moving average price is $39.60.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VERA. JPMorgan Chase & Co. cut their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Guggenheim boosted their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Wells Fargo & Company initiated coverage on Vera Therapeutics in a report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 target price for the company. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. Finally, Wolfe Research assumed coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.